The Effect of Helix-Inducing Constraints and Downsizing Upon a Transcription Block Survival Derived Functional cJun Antagonist

Research output: Contribution to journalArticlepeer-review

1 Citation (SciVal)

Abstract

Inhibition of cJun is established as a promising therapeutic approach, particularly in cancer. We recently developed the “transcription block survival” (TBS) screening platform to derive functional peptide antagonists of transcription factor activity by ablating their ability to bind to cognate DNA. Using TBS, we screened a >131,000-member peptide library to select a 63-mer peptide that bound cJun and prevented 12-O-tetradecanoylphorbol-13-acetate response element (TRE) DNA binding. Iterative truncation was next combined with a systematic exploration of side-chain cyclization to derive a minimal active sequence. The resulting dual lactamized sequence was >40% smaller and retained low nM target affinity (equilibrium binding constant [K D] = 0.2 versus 9.7 nM), with 8 residues at the acidic region required for functional antagonism. However, even modest C-terminal truncation resulted in functional loss. The peptide functionally antagonizes cJun (half-maximal inhibitory concentration [IC 50] = 13 versus 45 μM) and is considerably more stable in human serum relative to its non-lactamized counterpart and HingeW.

Original languageEnglish
Article number101077
JournalCell Reports Physical Science
Volume3
Issue number10
Early online date4 Oct 2022
DOIs
Publication statusPublished - 19 Oct 2022

Bibliographical note

Funding Information:
J.M.M. is grateful to Cancer Research UK (A26941) and the Medical Research Council (MR/T028254/1). J.M.M. and N.M.K. wish to thank the Biotechnology and Biological Sciences Research Council (BB/R017956/1, BB/R017921/1, and BB/T018275/1). A.B. conducted the experiments, while all authors contributed to the experimental design. J.M.M. and N.M.K. directed the research. All authors participated in data analysis and writing of the paper. J.M.M. is an advisor to Sapience Therapeutics. There are no other financial or commercial conflicts to declare.

Funding Information:
J.M.M. is grateful to Cancer Research UK ( A26941 ) and the Medical Research Council ( MR/T028254/1 ). J.M.M. and N.M.K. wish to thank the Biotechnology and Biological Sciences Research Council ( BB/R017956/1 , BB/R017921/1 , and BB/T018275/1 ).

Keywords

  • Peptide
  • antagonists
  • protein-protein interactions
  • transcription factor
  • activator protein-1
  • peptide cyclisation

Fingerprint

Dive into the research topics of 'The Effect of Helix-Inducing Constraints and Downsizing Upon a Transcription Block Survival Derived Functional cJun Antagonist'. Together they form a unique fingerprint.

Cite this